MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Pacific Biosciences of California Inc

Gesloten

SectorGezondheidszorg

2.21 -4.33

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.21

Max

2.39

Belangrijke statistieken

By Trading Economics

Inkomsten

3.9M

-38M

Verkoop

-1.3M

38M

Winstmarge

-98.853

Werknemers

575

EBITDA

3.2M

-32M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+2.13% upside

Dividenden

By Dow Jones

Volgende Winsten

12 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-66M

607M

Vorige openingsprijs

6.54

Vorige sluitingsprijs

2.21

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Pacific Biosciences of California Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jan 2026, 23:29 UTC

Populaire aandelen

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 jan 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 jan 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 21:48 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 jan 2026, 21:41 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 jan 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 jan 2026, 20:44 UTC

Winsten

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 jan 2026, 20:42 UTC

Marktinformatie

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 jan 2026, 20:28 UTC

Marktinformatie

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 jan 2026, 19:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 jan 2026, 18:53 UTC

Marktinformatie

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 jan 2026, 18:41 UTC

Marktinformatie

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 jan 2026, 18:31 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 jan 2026, 16:32 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 jan 2026, 16:20 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pacific Biosciences of California Inc Prognose

Koersdoel

By TipRanks

2.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.4 USD  2.13%

Hoogste 3 USD

Laagste 2 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacific Biosciences of California Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technische score

By Trading Central

1.13 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat